Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma

LYMPHOMA Clinical Trial

Official title:

Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03054532
• Other study ID #: SDBCC-LYM-16-01
• Status: Not yet recruiting
• Phase: Phase 2
• First received: February 13, 2017
• Last updated: February 15, 2017
• Start date: July 2017
• Est. completion date: July 2021

Study information

• Verified date: February 2017
• Source: Singapore General Hospital
• Contact: Colin Phipps, MD
• Phone: 6562223322
• Email: colin.phipps.diong[@]singhealth.com.sg
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multi-center, open-label, phase II study of durvalumab in combination with lenalidomide for treatment of relapsed/refractory NK/T-cell lymphoma (NKTCL). The study will employ a 2-stage Simon Optimal design with 80% power and type 1 error rate (significance level) of 5%. Stage 1 will involve 8 patients and will require at least 2 patients to achieve the primary end point of overall response in order to proceed onto to stage 2, which will have a target enrolment of 14 patients.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 22
• Est. completion date: July 2021
• Est. primary completion date: January 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 90 Years

Eligibility

Inclusion Criteria:

1. Histologically proven NK/T-cell lymphoma that has relapsed after at least one cycle of induction chemotherapy.

2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

3. Previously treated with at least one cycle of chemotherapy that includes L-asparaginase or gemcitabine.

4. Must be aged = 21 years and able to sign informed consent form.

5. Adequate hematological function (unless abnormalities are related to lymphoma infiltration of the bone marrow or hemophagocytic syndrome related to NKL) within 30 days prior to signing informed consent, including:

1. Absolute neutrophil count (ANC) = 1.0 x 109/L

2. Platelet count = 50 x 109/L

3. Hemoglobin = 8 g/dL

6. Must be able to adhere to study visit schedules and other protocol requirements.

7. Females of childbearing potential must:

1. Have 2 negative pregnancy tests as verified by a Study Investigator prior to starting study therapy. She must agree to ongoing pregnancy testing during the course of the study, and after end of study therapy. This applies even if the patient practices complete abstinence from heterosexual contact.

2. Either commit to complete abstinence from heterosexual contact or agree to use, and be able to comply with, effective contraception without interruption, 28 days prior to starting study drug, during the study therapy (including dose interruptions), and for 28 days after discontinuation of study therapy.

8. Male patients must practice complete abstinence or agree to use a condom during sexual contact with a pregnant female or female of childbearing potential while participating in the study, during dose interruptions and for 28 days after discontinuation of study therapy, even if he has undergone successful vasectomy.

9. All patients must:

1. Have an understanding that the study drug could have a potential teratogenic risk.

2. Agree to abstain from donating blood while taking study drug, during dose interruptions and for 28 days after discontinuation of study therapy.

3. Agree not to share study medication with another person.

4. Agree to be counseled about pregnancy precautions and risk of fetal exposure.

5. Females must agree to abstain from breast feeding during the study participation and for 28 days after discontinuation of study therapy.

10. Male subjects should not donate sperm or semen while taking lenalidomide, during breaks (dose interruptions), and for at least 28 days after the last dose of lenalidomide.

Exclusion Criteria:

1. Concomitant use of any other investigational agent.

2. Known infection with human immunodeficiency virus (HIV).

3. Patient has known clinically active hepatitis B; carriers of hepatitis B are permitted but need to be on appropriate anti-viral therapy or have regular hepatitis B DNA virus monitored as advised by a Gastroenterologist.

4. Subject has a calculated or measured creatinine clearance of < 30 mL/minute.

5. Neuropathy > Grade 2.

6. Presence of CNS involvement by lymphoma.

7. Myocardial infarction within 6 months prior to enrolment or has New York Hospital Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening has to be documented by the investigator as not medically relevant.

8. Clinically significant active infection or uncontrolled intercurrent illness.

9. Pregnant or lactating females.

10. Coexistent second malignancy or history of prior malignancy within the preceding 3 years (excluding non-melanoma skin tumors or in situ carcinoma of the cervix).

11. Any significant medical or psychiatric condition that might prevent the patient from complying with all study procedures.

Related Conditions & MeSH terms

• LYMPHOMA
• Lymphoma, T-Cell

Intervention

Drug:
• Durvalumab
Durvalumab intravenous 1500 mg
• Lenali
Lenalidomide oral 20 mg/day

Locations

Country	Name	City	State
Singapore	National Cancer Centre Singapore	Singapore
Singapore	National University Hospital Singapore	Singapore
Singapore	Raffles Hospital Singapore	Singapore
Singapore	Singapore General Hospital	Singapore

Sponsors (2)

Lead Sponsor	Collaborator
Singapore General Hospital	Celgene

Country where clinical trial is conducted

Singapore, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy as measured by overall response rate measured at the time of best response.	Overall response rate (ORR) is defined as the proportion of patients with reduction in tumor burden of at least 50%.	2 years
Secondary	Progression-free survival (PFS)	PFS is defined as the time from enrolment to progression or death due to any cause. The distribution of PFS will be estimated using the method of Kaplan-Meier.	2 years
Secondary	Overall survival (OS)	OS is defined as the time from registration to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier.	2 years
Secondary	Time-to-response (TTR)	Defined for all evaluable patients who have achieved an overall response as the date at which the patient's objective status is first noted to be a CR or PR.	2 years
Secondary	Duration of response (DoR)	Defined for all evaluable patients who have achieved an overall response as the date at which the patient's objective status is first noted to be a CR or PR to the earliest date progression is documented.	2 years